来特莫韦作为耐药巨细胞病毒视网膜炎的挽救治疗的应用。
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
机构信息
Duke University School of Medicine, Division of Infectious Diseases, Durham, North Carolina, USA
Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA.
出版信息
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02337-18. Print 2019 Mar.
Abstract
Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.
摘要
治疗药物耐药性巨细胞病毒 (CMV) 的方法有限。来特莫韦是一种新型抗病毒药物，最近被批准用于造血细胞移植后 CMV 的预防，但它在其他情况下的疗效尚不清楚。我们最近使用来特莫韦对 4 例更昔洛韦耐药的 CMV 视网膜炎的实体器官移植受者进行了挽救性治疗。所有患者的临床症状均有改善，无已知的药物不良反应。然而，有 3 名患者未能维持病毒学抑制，其中 2 名患者在治疗过程中发生了来特莫韦基因型确认耐药。
相似文献
1
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.来特莫韦作为耐药巨细胞病毒视网膜炎的挽救治疗的应用。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02337-18. Print 2019 Mar.
2
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).来特莫韦成功用于一名患有耐更昔洛韦巨细胞病毒综合征（UL97突变）的心脏移植受者的二级预防。
Transpl Infect Dis. 2018 Oct;20(5):e12965. doi: 10.1111/tid.12965. Epub 2018 Jul 20.
3
Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.来特莫韦作为移植受者巨细胞病毒感染的挽救治疗。
Transplantation. 2020 Feb;104(2):404-409. doi: 10.1097/TP.0000000000002785.
4
Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.实体器官移植受者中出现更昔洛韦耐药巨细胞病毒感染的来特莫韦耐药：病例系列和文献复习。
Transpl Infect Dis. 2021 Jun;23(3):e13515. doi: 10.1111/tid.13515. Epub 2020 Dec 6.
5
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.造血干细胞移植受者在二次莱曲莫韦预防治疗期间出现耐药巨细胞病毒的快速突破。
BMC Infect Dis. 2019 May 8;19(1):388. doi: 10.1186/s12879-019-4016-1.
6
Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.来特莫韦用于儿童造血干细胞移植受者耐巨细胞病毒挽救治疗的研究
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486-489. doi: 10.1093/jpids/piz050.
7
Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.目前关于来特莫韦和马拉韦罗治疗实体器官移植受者巨细胞病毒感染的观点。
Drug Des Devel Ther. 2024 Sep 6;18:3987-4001. doi: 10.2147/DDDT.S265644. eCollection 2024.
8
Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.成功治疗肾移植受者 UL97 突变更昔洛韦耐药巨细胞病毒血症：一例使用来特莫韦和辅助性抗巨细胞病毒免疫球蛋白的病例报告。
Transplant Proc. 2021 May;53(4):1284-1287. doi: 10.1016/j.transproceed.2021.02.001. Epub 2021 Mar 11.
9
An overview of letermovir: a cytomegalovirus prophylactic option.来特莫韦概述：一种巨细胞病毒预防选择。
Expert Opin Pharmacother. 2019 Aug;20(12):1429-1438. doi: 10.1080/14656566.2019.1637418. Epub 2019 Jul 8.
10
Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.来特莫韦用于预防成人异基因造血干细胞移植受者的巨细胞病毒表现。
Future Microbiol. 2019 Feb;14:175-184. doi: 10.2217/fmb-2018-0250. Epub 2019 Jan 15.
引用本文的文献
1
A novel strategy for the management of cytomegalovirus retinitis in immunocompromised patients using new anti-cytomegalovirus drugs.一种使用新型抗巨细胞病毒药物治疗免疫功能低下患者巨细胞病毒视网膜炎的新策略。
Front Med (Lausanne). 2025 Jun 11;12:1606985. doi: 10.3389/fmed.2025.1606985. eCollection 2025.
2
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.《实体器官移植中巨细胞病毒管理的第四届国际共识指南》
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.
3
CMV Retinitis in the Context of SARS-CoV-2 Infection: A Case Study and Comprehensive Review of Viral Interactions.2019冠状病毒病感染背景下的巨细胞病毒性视网膜炎：病例研究及病毒相互作用的全面综述
Pathogens. 2024 Oct 29;13(11):938. doi: 10.3390/pathogens13110938.
4
The Management of Hematopoietic Stem Cell Transplant in People with HIV.HIV 感染者造血干细胞移植的管理。
Viruses. 2024 Sep 30;16(10):1560. doi: 10.3390/v16101560.
5
Cytomegalovirus chronic retinal necrosis with ganciclovir resistance: a case report.耐更昔洛韦的巨细胞病毒性慢性视网膜坏死：一例报告
J Ophthalmic Inflamm Infect. 2024 Oct 8;14(1):50. doi: 10.1186/s12348-024-00434-w.
6
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.在一项治疗巨细胞病毒感染的随机3期临床试验中，马立巴韦与更昔洛韦耐药性的比较出现情况
J Infect Dis. 2025 Mar 17;231(3):e470-e477. doi: 10.1093/infdis/jiae469.
7
Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.目前关于来特莫韦和马拉韦罗治疗实体器官移植受者巨细胞病毒感染的观点。
Drug Des Devel Ther. 2024 Sep 6;18:3987-4001. doi: 10.2147/DDDT.S265644. eCollection 2024.
8
Recent advances in cytomegalovirus infection management in solid organ transplant recipients.近期实体器官移植受者巨细胞病毒感染管理的进展。
Curr Opin Organ Transplant. 2024 Apr 1;29(2):131-137. doi: 10.1097/MOT.0000000000001139. Epub 2024 Jan 30.
9
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.新型抗病毒药物来特莫韦和马瑞巴韦时代巨细胞病毒感染的管理
Infect Dis Rep. 2024 Jan 18;16(1):65-82. doi: 10.3390/idr16010005.
10
New Treatment Options for Refractory/Resistant CMV Infection.难治/耐药 CMV 感染的新治疗选择。
Transpl Int. 2023 Oct 12;36:11785. doi: 10.3389/ti.2023.11785. eCollection 2023.
本文引用的文献
1
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).来特莫韦成功用于一名患有耐更昔洛韦巨细胞病毒综合征（UL97突变）的心脏移植受者的二级预防。
Transpl Infect Dis. 2018 Oct;20(5):e12965. doi: 10.1111/tid.12965. Epub 2018 Jul 20.
2
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by Exposure to Letermovir and Ganciclovir.人巨细胞病毒 UL56 基因中雷帕霉素和更昔洛韦耐药新位点的揭示。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00922-18. Print 2018 Sep.
3
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
4
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.人巨细胞病毒末端酶复合物的第三个组成部分参与了乐韦莫及耐药性。
Antiviral Res. 2017 Dec;148:1-4. doi: 10.1016/j.antiviral.2017.10.019. Epub 2017 Oct 28.
5
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.接受膦甲酸钠治疗的耐更昔洛韦或难治性巨细胞病毒感染移植受者的结局
Transplantation. 2016 Oct;100(10):e74-80. doi: 10.1097/TP.0000000000001418.
6
Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.实体器官移植受者中耐更昔洛韦的巨细胞病毒感染：一项单中心回顾性队列研究。
Transpl Infect Dis. 2016 Jun;18(3):390-5. doi: 10.1111/tid.12537. Epub 2016 Jun 9.
7
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.导致来特莫韦耐药的人巨细胞病毒UL56突变的快速体外进化
Antimicrob Agents Chemother. 2015 Oct;59(10):6588-93. doi: 10.1128/AAC.01623-15. Epub 2015 Aug 10.
8
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.更昔洛韦预防造血细胞移植后巨细胞病毒感染。
N Engl J Med. 2014 May 8;370(19):1781-9. doi: 10.1056/NEJMoa1309533.
9
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.肺移植受者中更昔洛韦耐药巨细胞病毒感染与不良预后相关，尽管使用含膦甲酸酯的方案进行了治疗。
Antimicrob Agents Chemother. 2014;58(1):128-35. doi: 10.1128/AAC.00561-13. Epub 2013 Oct 21.
10
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.CMX001 预防造血细胞移植中的巨细胞病毒病。
N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.
Zotero 插件